---
format: Revealjs
bibliography: references.bib
---

## The Changing Landscape of Hematological <br> Malignancy Treatment {background-image="bonemarrow.png"}

<br>

### Implications for antifungal therapy

<br> <br>

<center>

Russell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Medical and Surgical Sciences <br> Infectious Diseases Unit- IRCCS S. Orsola University Hospitals <br> Alma Mater Studiorum Università di Bologna <br> Bologna, Italy

</center>

::: aside
May 17, 2022
:::

## Agenda

<br>

-   How will new therapies for hematological malignancies impact the epidemiology of invasive fungal infections?
-   What are the risks of toxicity and drug interactions with these newer therapies?
-   Is their a unique role for isavuconazole vs. other triazoles?

## The cure of leukemia through the optimist's prism

<br>

| Disease                                | Current/future therapies\*                                                                                                                                      | Survival (5 year) |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| **Hairy cell leukemia**                | Cladarabine + [gemtuzumab ozogamicin (GO)]{style="color:red;"}                                                                                                  | 90%               |
| **Acute premyelocytic leukemia**       | ATRA + arsenic ± [GO]{style="color:red;"}                                                                                                                       | 80-90%            |
| **AML (core binding factor positive)** | FLAG-[GO]{style="color:red;"} ± IDA, alloHSCT if MRD positive, if indicated, oral [AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors]{style="color:red;"} | 80-90%+           |
| **AML** <br>**(younger fit)**          | FLAG-IDA and [venetoclax]{style="color:red;"}, CLIA and [venetoclax]{style="color:red;"}                                                                        | 50-60%            |

::: aside
[@kantarjian2021; @kantarjian2022J] <br>

\*some therapies investigational or not licensed in Canada
:::

## 

| Disease                                                                   | Current/ future therapy\*                                                                                                                   | 5-10 year survival |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| **AML** <br> **(older, unfit, complex karyotype, T-53 mutations, MECOM)** | Low-intensity triple nucleosides (cladarabine, cytarabine and [HMAs + venetoclax; HMAs + venetoclax + targeted therapy]{style="color:red;"} | 40-50%             |
| **ALL \< 60 years**                                                       | HyperCVAD + [CD19/CD20 targeted antibodies]{style="color:red;"}                                                                             | 60-70%             |
| **ALL \> 60 years**                                                       | Mini-hyper CVAD+ [inotuzumab; blinatumab + ponatinib]{style="color:red;"}                                                                   | 50%                |
| **Ph-positive ALL**                                                       | HyperCVAD + [ponatinib; blinatumab + ponatinib]{style="color:red;"}                                                                         | 70-80%?            |
|                                                                           |                                                                                                                                             |                    |

::: aside
[@kantarjian2021; @kantarjian2022J] <br>

\*some therapies investigational or not licensed in Canada
:::

## 

<br>

| Disease | Current/ future therapy\*                                                                                                  | 5-10 year survival |
|---------|----------------------------------------------------------------------------------------------------------------------------|--------------------|
| **CML** | [BCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib)]{style="color:red;"}, alloHSCT | 85-90%             |
| **CLL** | [Ibrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)]{style="color:red;"}                                  | 80-90% +           |
| **MDS** | [Parenteral HMAs, oral HMAs, venetoclax, others]{style="color:red;"}                                                       | 40% +              |

::: aside
[@kantarjian2021] <br>

\*some therapies investigational or not licensed in Canada
:::

## <br> <br> <br> <br> <br>How is invasive fungal disease risk altered <br> by targeted therapies? {background-image="bonemarrow.png"}

## Unexpected consequences of targeted therapy?

<br>

![](burger_NEJM.png){fig-align="center" width="3028"}

::: aside
[@burger2015; @chamilos2018]
:::

## Ibrutinib-associated aspergillosis

::: columns
::: {.column width="50%"}
<br>

<div>

![](MRI.png){fig-align="left"}

</div>
:::

::: {.column width="50%"}
<br>

<br>

-   Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL
-   [CNS aspergillosis in 11/27 (40%)]{style="color:red;"}, most cases within 3 months of starting therapy
-   All patients had refractory/relapsed CLL and other predisposing risk factors
:::
:::

::: aside
[@ghez2018; @chamilos2018]
:::

## Fungal infections in patients receiving <br> ibrutinib for lymphoid cancers

::: columns
::: {.column width="60%"}
<center>

Data from MSKCC, New York

</center>

<div>

![](ibrutinib_onset.png)

</div>
:::

::: {.column width="40%"}
<br> <br>

-   **In a second, retrospective study from MDACC (2014-2018):**
    -   21 (2.5%) with proven/probable invasive mold infection
    -   Primarily pneumonia
    -   Primary fungus: *Aspergillus* spp.
    -   Risk factors: monocytopenia, ≥ 3 prior CLL therapies
:::
:::

::: aside
[@varughese2018; @frei2020J]
:::

## 

![](Lancet%20_DI.png)

![](Lancet%20Haematology.png){fig-align="center"}

::: aside
[@bruggemann2022; @stemler2022J]
:::

## Managing fungal infection risks with <br> novel therapies for AML

### EHA consensus recommendations

<br>

-   Systematic review of the literature, recommendations developed using GRADE framework (4977 publications evaluated)
-   Outcomes evaluated:
    -   Incidence of invasive fungal disease (IFD)
    -   Prolongation of hospitalization
    -   Days spent in ICU/mortality associated with IFD
    -   Potential DDIs
-   **Evidence-based recommendations were developed for hypomethylating agents (HMAs), midostaurin, venetoclax-HMA combinations**

::: aside
[@stemler2022J]
:::

## Summary of EHA recommendations-1

<br>

-   **Hypomethylating agent monotherapy:**
    -   Standard use or prophylaxis not recommended
    -   Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy → conditional recommendation for prophylaxis
-   **FLT3 inhibitors (midostaurin, gilteritinib)**
    -   Antifungal prophylaxis recommended during induction chemotherapy
    -   Conditional recommendation for prophylaxis during consolidation in patients with risk factors (prior IFI, prolonged neutropenia)
    -   Lack of clear medical guidance for managing drug interactions
    -   Close monitoring favoured over empiric FLT-3 inhibitor dose reduction

::: aside
[@stemler2022J]
:::

## Summary of EHA recommendations-2

<br>

-   **Venetoclax**
    -   Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy, or prolonged neutropenia with venetoclax
    -   Conditional recommendation to administer prophylaxis
    -   Careful management of drug interactions with triazoles

::: aside
[@stemler2022J]
:::

## Venetoclax dose-adjustment with triazoles

<br>

<center>

Venetoclax + hypo-methylating agents for AML;

Co-administration with posaconazole ↑ venetoclax AUC 8-fold

</center>

<br>

|          |               |                                       |                                     |
|----------|---------------|---------------------------------------|-------------------------------------|
| **Day**  | **Full dose** | **Moderate**[^1] **CYP3A4 inhibitor** | **Strong**[^2] **CYP3A4 inhibitor** |
| Day 1    | 100 mg        | 50 mg                                 | 10 mg                               |
| Day 2    | 200 mg        | 100 mg                                | 20 mg                               |
| Day 3    | 400 mg        | 200 mg                                | 50 mg                               |
| Day 4-28 | 400 mg        | 200 mg                                | 70 mg                               |

::: aside
[@stemler2022J; @bhatnagar2021J]
:::

## Triazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax

<br>

![](venetoclax_Rausch.png){fig-align="center"}

::: aside
[@rausch2019]
:::

## CYP450 Interactions: The achilles heel of triazoles

<center>

75-85% of patients receiving mold-active triazoles have serious drug interactions

</center>

![](cyp_interactions.png){fig-align="center" width="600"}

<br>

::: aside
[@bruggemann2009a; @andes2016]
:::

## PK/PD Properties of Small Molecule Kinase Inhibitors {.smaller}

<br> <br>

| Drug                  | Venetoclax                   | Midostraurin                 | Gilteritinib                     | Ivosidenib                     | Enasidinib                                                  | Glasdegib                      |
|-----------------------|------------------------------|------------------------------|----------------------------------|--------------------------------|-------------------------------------------------------------|--------------------------------|
| Specificity (targets) | BCL2                         | FLT3                         | FLT3                             | IDH1                           | IDH2                                                        | Hedgehog pathway               |
| Hepatic               | [CYP3A4]{style="color:red;"} | [CYP3A4]{style="color:red;"} | [CYP3A4/5]{style="color:red;"}   | [CYP3A4/5]{style="color:red;"} | [Multiple CYP enzymes including CYP3A4]{style="color:red;"} | [CYP3A4/5]{style="color:red;"} |
| Efflux                | Substrate of PgP, BCRP       | Not a substrate              | Substrate of PgP, not BCRP, OATP | Substrate PgP, but not BRCP    | Not a substrate of BCRP pr PgP                              | Substrate for PGP, BCRP        |

::: aside
[@megias-vericat2020J]
:::

## Toxicities of small-molecule kinase inhibitors

![](targeted%20therapy%20toxicities.png){fig-align="center"}

::: aside
[@wang2020a]
:::

## Just avoid triazoles?

<br>

![](avoid%20triazoles.png){fig-align="center"}

## The problems with echinocandin prophylaxis

<br>

![](echinocandin.png){fig-align="center"}

::: aside
[@gomes2014]
:::

## <br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs. other triazoles? {background-image="bonemarrow.png"}

## 

![](spec.png){fig-align="center"}

## Pharmacokinetic complexity of voriconazole

<br>

![](voriconazole%20PK.png){fig-align="center"}

::: aside
[@trifilio2014]
:::

## Triazole toxicities

<br>

![](triazole%20toxicity.png){fig-align="center"}

::: aside
[@Lewis2011805; @johnson2021]
:::

## 

<br>

![](registry.png){fig-align="center"}

::: aside
[@ostroskey-zeichnerluis2021J]
:::

## Triazole safety

<br>

-   Multicenter registry of prophylaxis (n=1777) and treatment (n=816) courses
-   Adverse effects leading to treatment discontinuation:
    -   voriconazole (n=494) 14.2%
    -   posaconazole (n=547) 11.3%
    -   isavuconazole (n=514) 3.9%
    -   multiple/sequenced therapy (n=454) 11.7%
-   QTc prolongation was rare, but more frequent with voriconazole and posaconazole
-   Severe drug interactions occurred in 4% of all treated patients
-   IFI mortality rates were similar for all agents ranging between 1.1-1.8%

::: aside
[@ostroskey-zeichnerl2021J]
:::

## What makes isavuconazole <br>(isavuconazonium) unique?

::: columns
::: {.column width="40%"}
<br>

<div>

![](isavuconazole.png){fig-align="left"}

</div>
:::

::: {.column width="60%"}
<br>

-   Broad spectrum of activity
-   Prodrug IV/ oral formulations (\> 90% bioav.)
-   Predictable linear PK, t~1/2~=130h
-   Less need for TDM
-   Better safety profile than voriconazole
    -   Less potent CYP3A4/5 inhibition
    -   Less cutaneous, CNS, hepatic toxicities
    -   Does not prolong QT
:::
:::

::: aside
[@johnson2021; @maertens2016]
:::

## QT prolongation risk with triazoles

::: columns
::: {.column width="40%"}
<br>

![](QTC.png){width="400"}
:::

::: {.column width="60%"}
<br>

<br>

-   Older triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K^+^ rectifier current
-   Isavuconazole shortens cardia QT in a dose-related manner, with no associated cardiac risk
    -   hCav1.2 L-type Ca^++^ channels
:::
:::

::: aside
[@keirns2017]
:::

## Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE) {.smaller}

![](Secure.png){fig-align="center" width="400"}

<br>

::: aside
[@maertens2016]
:::

## Treatment-emergent adverse effects <br> in the SECURE trial

<br>

-   Hepatobiliary disorders (VOR-16% vs. ISA-9%, p=0.016)
-   Visual disturbances (VOR-27% vs. ISA-15%, p=0.002)
-   Skin or subcutaneous tissue (VOR-42% vs. ISA-33%, p=0.037
-   **Overall drug-related AE (VOR-60% vs. ISA-42%, p\<0.001)**

::: aside
[@maertens2016]
:::

## Isavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)

![](isavuconazole_Mucor.png){fig-align="center" width="600"}

::: aside
[@marty2014]
:::

## Isavuconazole drug interaction potential

<br>

+-----------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+
| Drug                        | Pharmacokinetic change                      | Initial management                                                                                                    |
+=============================+=============================================+=======================================================================================================================+
| Tacrolimus                  | ↑ AUC 1.8-3xfold                            | 40-50% reduction in tacrolimus dose, TDM. Some studies suggest no empiric dose reduction was required                 |
|                             |                                             |                                                                                                                       |
|                             | ↑ C~max~ 1.4-2.8xfold                       |                                                                                                                       |
+-----------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+
| Prednisone/ <br>Prednislone | ↑ AUC (8%) minimal                          | No dose adjustments recommended                                                                                       |
+-----------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+
| Ruxolitinib                 | ↑AUC and C~max~ by an average of 27% and 8% | Although dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with isavuconazole |
+-----------------------------+---------------------------------------------+-----------------------------------------------------------------------------------------------------------------------+

::: aside
[@kufel2018;@kieu2019; @groll2017b; @ouatas2017;]
:::

## Isavuconazole drug interaction potential

<br>

+------------------+-------------------------+--------------------------------------------------------------+
| Drug             | Pharmacokinetic change  | Initial management                                           |
+==================+=========================+==============================================================+
| **Venetoclax**   | ↑AUC 2-3.9xfold         | Dose reduction of venetoclax by 50%                          |
+------------------+-------------------------+--------------------------------------------------------------+
| **Midostaurin**  | ↑AUC 1.44xfold higher   | No dose reduction recommended for moderate CYP3A4 inhibitors |
+------------------+-------------------------+--------------------------------------------------------------+
| **Gilteritinib** | ↑AUC 1.4xfold; <br>     | No dose reduction recommended for moderate CYP3A4 inhibitors |
|                  |                         |                                                              |
|                  | ↑C~max~ 1.2-fold higher |                                                              |
+------------------+-------------------------+--------------------------------------------------------------+

::: aside
[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]
:::

## Are the theoretical differences clinically important?

![](Menna_midostraurin.png){fig-align="center"}

::: aside
[@Menna2021-mb]
:::

## 

![](Bose%20study.png){fig-align="center"}

::: aside
[@bose2020]
:::

## 

![](bose2.png){fig-align="center"}

::: aside
[@bose2020]
:::

## 

![](bose3.png){fig-align="center"}

::: aside
[@bose2020]
:::

## 

![](bose4.png){fig-align="center"}

::: aside
[@bose2020]
:::

## Isavuconazole tolerability

<br>

<br>

::: columns
::: {.column width="50%"}
-   **Posaconazole experience**
-   [Grade III/IV liver injury with tablet and IV formulations (9%)]{style="color:red;"}
-   Primary hyperbilirubinemia
-   Higher frequency in patients with serum levels \> 1,830 ng/mL
:::

::: {.column width="50%"}
-   **Isavuconazole (current study)**
-   [Grade 1 transaminitis (2.7%)]{style="color:red;"}
-   Grade 2 elevated T. bilirubin (1.3%)
-   No elevations in QTc detected vs. baselines at 10 days
:::

<br>

[@bose2020]
:::

## 

![](bose5.png){fig-align="center"}

<br>

<br>

<div>

[@Young2021-jx]

</div>

## Jo-Anne H. Young, *Clin Infect Dis 2021*

<br>

<br>

"This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.

<br>

"Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed."

## Summary {background-image="bonemarrow.png"}

<br>

-   Knowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the treatment scenario
-   Many small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult
-   Isavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies

## Thank you for your attention!

![](bologna%202.png){.absolute top="200" left="0" width="442" height="303"}

![](bologna3.png){.absolute top="50" right="50" width="450" height="250"}

![](Screenshot%202022-05-16%20at%2012.30.29.png){.absolute bottom="0" right="50" width="418" height="273"}

## References

<br>

All figures created by R. Lewis using www.biorender.com <br> <br>

[^1]: fluconazole, isavuconazole

[^2]: voriconazole, posaconazole
